Patent · US Active

Dual mechanism inhibitors for the treatment of disease

US8394826B2 · kind B2 · utility

44Cited by

19References

33Claims

0Family size

Assignee

Aerie Pharmaceuticals, Inc. · US

Inventors

Mitchell A. deLong · Chapel Hill, US
Jill Marie Sturdivant · Chapel Hill, US
Susan M. Royalty · Cary, US

Key dates

Filing date	Jan 27, 2010
Grant date	Mar 12, 2013
Priority date	—
Expiry date	Nov 10, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C2601/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.